Magnum Ventures (MAGNUM)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at P/B 0.22, a 78% discount to book value of ₹101.30 versus price ₹21.89.
• Debt/Equity is modest at 0.39, suggesting limited balance-sheet stress.
• Promoter holding of 55.21% aligns insider interests with minority shareholders.
• Market cap of ₹149 Cr is far below stated book value, offering asset-based downside cushion.

Concerns

• Annual profit growth has collapsed by -96.81%; latest quarter net profit is ₹0 Cr, leaving no earnings support.
• ROE is negative at -1.62% and ROCE is just 3.68%, indicating poor returns on capital.
• Sales growth is -1.24%, and the paper business shows no clear demand recovery.
• Piotroski F-Score of 3/9 signals weak financial health and possible operational stress.

AI Analysis

At ₹21.89, Magnum Ventures is offered at a striking 78% discount to its book value of ₹101.30. A price-to-book of 0.22 would catch any Graham student's attention. But cheap is not the same as good. The business earns a ROCE of only 3.68% and its ROE is negative at -1.62%. The latest quarter net profit is zero, and annual profit growth has collapsed by 96.81%. This is a commodity paper business with no visible pricing power, no dividend, and no earnings engine. The Piotroski F-score of 3/9 reinforces my caution. Debt/equity at 0.39 is not alarming, and promoter holding at 55.21% does align interests. But a stock trading below book value makes sense only if the assets are real and can eventually earn a proper return. Paper is cyclical, so perhaps the cycle will turn. Yet sales are still declining by 1.24%, and there is no evidence of margin recovery. I would not confuse a cigar butt with a wonderful business. If I invest, it is as an asset play: the downside may be partly cushioned by book value, but the upside depends on operating performance. I need to see earnings revive before applying a normal earning-power valuation. As of now, this is a speculation on asset realization and cyclical recovery, not a compounder. The apparent margin of safety is wide, but the quality of the business is low. In Graham's language, this would be appealing only if the book assets are conservatively stated. For now, I would keep it on the watchlist and wait for demonstrable improvement in returns.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer